Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 314 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy Volunteers
Interventions
Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Schizophrenic Disorders
Interventions
LY2140023, Placebo, Moxifloxacin
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Garden Grove, California • San Diego, California • North Miami, Florida + 5 more
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Cataract
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Withdrawn Phase 1 Interventional Accepts healthy volunteers

QTc Study of Rosi XR in Healthy Volunteers

NCT00884533
Conditions
Alzheimer's Disease
Interventions
Rosi XR, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Phase 2 Interventional Results available

Males, Antioxidants, and Infertility Trial

NCT02421887
Conditions
Male Infertility
Interventions
Antioxidant Supplement, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Sunnyvale, California + 7 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Conditions
Healthy
Interventions
sisunatovir, placebo, moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF 4226 pMDI, Placebo, Moxifloxacin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Cardiac Conduction of GSK1349572

NCT00996021
Conditions
Healthy Subjects
Interventions
GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Epithelium, Corneal
Interventions
Moxifloxacin, Gatifloxacin
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Cataract Extraction
Interventions
Moxifloxacin 0.5% ophthalmic solution, Besifloxacin 0.6% ophthalmic suspension
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Intraabdominal Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 17 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Diego, California • Springfield, Massachusetts
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Conditions
Ventricular Repolarization
Interventions
DIC075V
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 1 Interventional Accepts healthy volunteers

A Cardiac Liability Study of Varegacestat in Healthy Participants

NCT06855264
Conditions
Healthy Volunteer
Interventions
varegacestat, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Healthy
Interventions
granisetron
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Conditions
Endophthalmitis
Interventions
Moxifloxacin, Placebo
Drug
Lead sponsor
Jason Ahee, M.D.
Industry
Eligibility
40 Years and older
Enrollment
60,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
St. George, Utah
Conditions
Healthy
Interventions
Rodatristat Ethyl, Moxifloxacin, Placebo for Rodatristat, Placebo for Moxifloxacin
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Systemic Lupus Erythematosus, Healthy Participants
Interventions
BMS-986165, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Terminated Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

NCT00460759
Conditions
Mycobacterium Tuberculosis
Interventions
Moxifloxacin, Rifapentine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland